Hera Health Solutions

Success Stories of Long-Acting Drugs (Pt. 2): ? Low patient compliance and repetitive treatments are signs that a long-acting drug can disrupt the market. Pfizer and OPKO entered 40+ markets after introducing their long-acting GH-deficiency treatment. Check out today's case study ???? ???????????? Our technology at Hera Health Solutions turns APIs into long-acting drugs. Send the direct message “Long-acting” to Hera’s LinkedIn inbox to explore your API’s

Success Stories of Long-Acting Drugs (Pt. 1): ? Low patient compliance, side effects, and repetitive treatments are signs that a long-acting drug can disrupt the market. Gilead made $50B+ in 3 years by spotting this opportunity. Check out today's case study ???? And stay tuned for more. ???????????? Our technology at Hera Health Solutions turns APIs into long-acting drugs. Send the direct message “Long-acting” to Hera’s LinkedIn inbox to explore your API’s potential.

Imagine we cure colorectal, prostate, and breast cancers ??? How many lives could we save? Surprisingly, That’s about as many lives as if patients took their medication on time. Yet, most patients skip medications—more so if they have to take the pill every day. How can pharma handle this? Of course, our intuitive answer would be educating patients about finishing their blister packs. ?? But the data suggests a smarter solution: Lower dosing frequency boosted patient compliance in nearly all diseases. (Example: Taking a pill a week instead of every day). ?? This means changing the pill works better than changing the patient. Turning APIs into longer-acting treatments makes them safer, more precise, and more convenient for patients. This way, pharma can save lives, stop budget bleeding, and make their drugs more profitable. Healthcare is heading towards precision, and long-acting drugs are leading the charge. ???????????? Our technology at Hera Health Solutions turns drugs into long-acting treatments. Send the direct message “Long-acting” to Hera’s LinkedIn inbox to explore your API’s potential.

?? Key takeaways: 1. Non-compliance (non-adherence) costs about as many lives as colorectal, prostate, and breast cancers combined (125,000 lives per year in the US alone) 2. Awareness cannot be a one-size-fits-all solution because patients skip medications for different reasons 3. Those reasons are often disease-dependent (e.g. stigma is a powerful driver of skipping psychiatric medications, whereas fear of side effects is a more cause in patients with chronic conditions) 4. There is consistent proof that lower dosing frequency increases patient adherence—helping pharma address the trillion-dollar adherence problem 5. Innovative DDS’s help both pharma (more profitable therapeutics) and patients (better outcomes) ???????????? Our technology at Hera Health Solutions turns drugs into long-acting treatments. Send the direct message “Long-acting” to Hera’s LinkedIn inbox to explore your API’s potential.

Low compliance costs pharma $1T in annual revenue. How can we recover this loss? Rory Sutherland's solution is brilliant. But unfortunately, it falls short of recovering the full $1T. In one of his talks, The Vice Chairman of Ogilvy & Mather suggested: ??? "If you want people to finish their antibiotics, don't give them 24 white pills. Give them 18 white pills and six blue ones and say, 'When you finish the white pills, take the blue ones.' The pills can be identical. People will simply be more likely to finish a course of treatment if it comes in two sequential colors. Fact." Sutherland’s solution can help more patients get through their blister packs, but it still wouldn’t solve: ? Forgetfulness—especially older patients with amnesia ? Low motivation when symptoms are not present ? Dosing issues ? Side effects ? Low health literacy ?? Luckily, there's a better way: Turning APIs into longer-acting treatments makes them safer, more precise, and more convenient for patients. Solving patient non-compliance can save about as many lives as curing colorectal, prostate, and breast cancer (combined*). For pharma ?? adopting long-acting technologies can: ? Save lives ? Stop healthcare budget bleeding ? And make drugs more profitable Healthcare is heading towards precision. Long-acting drugs are leading the charge. ???????????? Our technology at Hera Health Solutions turns drugs into long-acting treatments so patients can take fewer doses that last up to 48 months. Send the direct message “Long-acting” to Hera’s LinkedIn inbox to explore your API’s potential. Photo credit: TED *Baryakova TH et al. Nat Rev Drug Discov. (2023)

You can turn your API into a long-acting precision treatment—Eucontra? is proof ???? Send the direct message “Long-acting” to Hera’s LinkedIn inbox to explore your API’s potential.

A big thank you to our summer interns at Hera Health Solutions! You tackled complex projects with impressive results and made meaningful contributions to our mission. We’re especially grateful to First Tech Fund for partnering with us to help bring such talented individuals to our team. Wishing you all the best as you continue your journeys! Punnasri D Aaliyah Balogun Nina Zimmerman James White #BiotechInternship?#DrugDelivery #Biotechnology #LifeScience #RedefiningDrugDelivery

We’re excited to introduce our new summer internship program with a partnership from Ladder Internships! Their dedication, creativity, and hard work over the past few months have been instrumental in advancing our mission at Hera Health Solutions -?pushing the boundaries of drug delivery innovation! Thank you for your invaluable contributions and commitment.?Here's to a bright future ahead! #Interns #LadderInternships #DrugDelivery #Biotechnology #HeraHealthSolutions